Evidence map›Paper›PMID 38922438›Full record

ArticleEmerging microbes & infections2024

Active surveillance of hepatitis E: a 10-year epidemiological analysis in a city in eastern China.

Xingcheng Huang, Xiaoxiang Zheng, Lin Chen, Chunlan Zhuang, Changlin Yang, Xia Zang, Yijun Wang, Hanmin Jiang, Xiaomeng Huang, Qiang Yan and 10 more

Abstract read
In one paragraph

Article in Emerging microbes & infections, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Xingcheng HuangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, People's Republic of China.
Xiaoxiang ZhengDongtai Center for Disease Control and Prevention, Dongtai, People's Republic of China.
Lin ChenDongtai Center for Disease Control and Prevention, Dongtai, People's Republic of China.
Chunlan ZhuangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, People's Republic of China.
Changlin YangDongtai Center for Disease Control and Prevention, Dongtai, People's Republic of China.
Xia ZangDongtai Center for Disease Control and Prevention, Dongtai, People's Republic of China.
Yijun WangDongtai Center for Disease Control and Prevention, Dongtai, People's Republic of China.
Hanmin JiangDongtai Center for Disease Control and Prevention, Dongtai, People's Republic of China.
Xiaomeng HuangDongtai Center for Disease Control and Prevention, Dongtai, People's Republic of China.
Qiang YanXiamen Innodx Biotech Company, Xiamen, People's Republic of China.
Zimin TangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, People's Republic of China.
Yingying SuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, People's Republic of China.
Zizheng ZhengState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, People's Republic of China.
Ting WuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, People's Republic of China.
Xuefeng ZhangJiangsu Provincial Center for Disease Control and Prevention, Nanjing, People's Republic of China.
Yue HuangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, People's Republic of China.
Shoujie HuangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, People's Republic of China.
Fengcai ZhuJiangsu Provincial Center for Disease Control and Prevention, Nanjing, People's Republic of China.
Jun ZhangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, People's Republic of China.ORCID 0000-0002-6601-9180
Ningshao XiaState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, People's Republic of China.ORCID 0000-0003-0179-5266

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis E virus (HEV) is an important cause of acute hepatitis, however, is highly neglected and largely underreported. This study aimed to describe the detailed epidemiology of hepatitis E (HE) through a 10-year surveillance. A community-based active hepatitis surveillance was conducted between November 2007 and October 2017 in 11 townships of Dongtai City in China, involving 355,673 residents. Serum samples were obtained from patients presenting with hepatitis symptoms for more than 3 days. Serum alanine aminotransferase (ALT) levels greater than 2.5 times the upper limit of normal (ULN) were considered acute hepatitis. Samples were subsequently tested for IgG and IgM anti-HEV antibodies, HEV RNA, and hepatitis B surface antigen (HBsAg). The data indicated the incidence of HE fluctuated downward from 2007 to 2017, with an average annual age-standardized incidence of 17.50 per 100,000, exceeding the 10.26 per 100,000 in the National Notifiable Disease Report System (NNDRS). The incidence was notably higher among males (20.95 per 100,000) and individuals aged 50-69 years (37.47 per 100,000). Genotype 4 (HEV-4) was the predominantly circulating genotype during the study period. Furthermore, the study revealed the incidence of hepatitis with HEV and hepatitis B virus (HBV) co-infection was 4.99 per 100,000. The active surveillance system identified a higher incidence of HE compared to NNDRS, with a decreased prevalence over a 10-year period. While efforts are still needed to prevent HE in high-risk populations, including individuals with hepatitis B and the elderly.

Indexed as

Hepatitis AntibodiesHepatitis EHepatitis E virusAdolescentAdultAgedAged, 80 and overChildChild, PreschoolChinaCitiesCoinfectionEpidemiological MonitoringFemaleGenotypeHepatitis BHepatitis AntibodiesHepatitis B Surface AntigensImmunoglobulin GImmunoglobulin MRNA, Viraldisease notificationepidemiologyhepatitis BHepatitis Esurveillance

Identifiers

PMID38922438
PMCPMC11257014

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.